source
- Argenx to acquire Forte Biosciences for $2.2 billion, adding anti-CD122 antibody FB102Argenx announced it will buy Texas‑based Forte Biosciences in a transaction valued at roughly $2.2 billion. The offer of $77 per share represents an 86 % premium to Forte’s recent average price. T…
- Apnimed targets up to $160 million IPO to fund launch of Oxnimbi, its oral sleep apnea pillApnimed, a Massachusetts biotech, filed with the SEC indicating it will seek an IPO of up to $160 million to finance the commercial launch of its oral obstructive sleep apnea therapy, Oxnimbi (AD10…